Secretome Therapeutics
Secretome Therapeutics, a clinical-stage biotechnology company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the appointment of Marshelle Smith Warren, MD, as Chief Medical Officer. Dr. Warren is a highly experienced pharmaceutical executive with over two decades of leadership in clinical development, translational medicine, and regulatory strategy across multiple therapeutic areas, including cell therapy, immunology, cardiovascular, and rare diseases.
